The relationship between high-sensitivity CRP and polyclonal Free Light Chains as markers of inflammation in chronic disease

International Journal of Laboratory Hematology

Volumn 36, Issue 4, 2014, Pages 415-424

  Burmeister, A ^a,b   Assi, L K ^b   Ferro, C J ^a,c   Hughes, R G ^b   Barnett, A H ^a,c   Bellary, S ^a,d   Cockwell, P ^a,c   Pratt, G ^a   Hutchison, C A ^a,c,e  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b Binding Site Group Ltd   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d ASTON UNIVERSITY   (United Kingdom)

^e Hawke's Bay District Health Board   (New Zealand)

Author keywords

C reactive protein; Inflammation; Risk stratification; Serum free light chains

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; IMMUNOGLOBULIN LIGHT CHAIN; POLYCLONAL FREE LIGHT CHAIN; UNCLASSIFIED DRUG;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC DISEASE; CHRONIC KIDNEY DISEASE; CHURG STRAUSS SYNDROME; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; FEMALE; HUMAN; INFLAMMATION; INNATE IMMUNITY; INTENSIVE CARE; KIDNEY TRANSPLANTATION; LIGHT CHAIN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MICROSCOPIC POLYANGIITIS; POLYARTERITIS NODOSA; PRIORITY JOURNAL; VASCULITIS; WEGENER GRANULOMATOSIS; BLOOD; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC; SYSTEMIC VASCULITIS; VERY ELDERLY;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; FEMALE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; INFLAMMATION; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; SYSTEMIC VASCULITIS;

EID: 84904399388     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/ijlh.12159     Document Type: Article

References (31)

1. Hutchison CA, Landgren O. Polyclonal immunoglobulin free light chains as a potential biomarker of immune stimulation and inflammation. Clin Chem 2011;57:1387-9.
2. Hutchison CA, Harding S, Hewins P, Mead GP, Townsend J, Bradwell AR, Cockwell P. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol 2008;3:1684-90.
3. Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, Drew R. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001;47:673-80.
4. Pratt G. The evolving use of serum free light chain assays in haematology. Br J Haematol 2008;141:413-22.
5. Maignan M, Driad A, Jacob C, Jay N, Dousset B, Vignaud JM, De Korwin JD. Sjögren's syndrome and serum free light chain analysis in newly diagnosed patients. Hematol Rep 2010;2:E47a.
6. Jolly M, Aggarwal R, Francis S, Mikolaitis AR, Niewold T, Chubinskaya S, Block JA, Sequeira W. Serum free light chains and disease activity in systemic lupus erythematosus. Hematol Rep 2010;2:E46a.
7. Aggarwal R, Sequeira W, Kokebie R, Mikolaitis RA, Fogg L, Finnegan A, Plaas A, Block JA, Jolly M. Serum free light chains as biomarkers for systemic lupus erythematosus disease activity. Arthritis Care Res 2011;63:891-8.
8. Gottenberg J. Free light chains of immunoglobulins as disease markers in autoimmune diseases. Hematol Rep 2010;2:p14.
9. Landgren O. Circulating serum free light chains as predictors of AIDS lymphoma and beyond. Hematol Rep 2010;2:p13.
10. Tsai HT, Caporaso NE, Kyle RA, Katzmann JA, Dispenzieri A, Hayes RB, Marti GE, Albitar M, Ghia P, Rajkumar SV, Landgren O. Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study. Blood 2009;114:4928-32.
11. Tillett WS, Goebel WF, Avery OT. Chemical and immunological properties of a species-specific carbohydrate of pneumococci. J Exp Med 1930;52:895-900.
12. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
13. Miyake K, Imura S, Nishioka M, Batmunkh E, Sugimoto K, Ohmoto Y, Shimada M. Serum evaluation of soluble interferon-alpha/beta receptor and high-sensitivity C-reactive protein for diagnosis of the patients with gastrointestinal and hepatobiliary-pancreatic cancer. Cytokine 2010;49:251-5.
14. Vervoort G, Willems HL, Wetzels JF. Assessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: validity of a new (MDRD) prediction equation. Nephrol Dial Transplant 2002;17:1909-13.
15. Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR, Kyle RA. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002;48:1437-44.
16. Wilkins J, Gallimore JR, Moore EG, Pepys MB. Rapid automated high sensitivity enzyme immunoassay of C-reactive protein. Clin Chem 1998;44:1358-61.
17. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 1997;43:52-8.
18. Swinscow T. Correlation and regression. Statistics at Square One in BMJ Publishing, 1997.
19. Bradwell AR. Serum Free Light Chain Analysis (plus Hevylite), 6th edn. Birmingham, UK: The Binding Site Group Ltd; 2010.
20. 131I] Bence Jones protein catabolism in human subjects. Clin Chim Acta 1967;18:395-407.
21. Kim J, Hayton WL, Robinson JM, Anderson CL. Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model. Clin Immunol 2007;122:146-55.
22. Morell A, Skvaril F, Noseda G, Barandun S. Metabolic properties of human IgA subclasses. Clin Exp Immunol 1973;13:521-8.
23. Barth WF, Wochner RD, Waldmann TA, Fahey JL. Metabolism of human gamma macroglobulins. J Clin Invest 1964;43: 1036-48.
24. Assi L, McClean A, Webb G, Harper L, Hutchison CA. Serum polyclonal free light chain levels in patients with vasculitis. J Am Soc Nephrol 2011;22:FR-PO1887a.
25. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003;111:1805-12.
26. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-54.
27. Gupta J, Mitra N, Kanetsky PA, Devaney J, Wing MR, Reilly M, Shah VO, Balakrishnan VS, Guzman NJ, Girndt M, Periera BG, Feldman HI, Kusek JW, Joffe MM, Raj DS. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc Nephrol 2012;7:1938-46.
28. Booth AD, Jayne DR, Kharbanda RK, McEniery CM, Mackenzie IS, Brown J, Wilkinson IB. Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation 2004;109:1718-23.
29. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-34.
30. Dispenzieri A, Katzmann JA, Kyle RA, Larson DR, Therneau TM, Colby CL, Clark RJ, Mead GP, Kumar S, Melton LJ III, Rajkumar SV. Use of nonclonal serum immunoglobulin free light chains to predict overall survival in the general population. Mayo Clin Proc 2012;87:517-23.
31. Dürig J, Eisele L, Hüttmann A, Dührsen U, Führer A, Kieruzel S, Bokhof B, Erbel R, Mann K, Jöckel KH, Moebus S. Polyclonal free light chain elevation and mortality in the German Heinz Nixdorf Recall study. Hematol Rep 2010;2:p13.